HAPPENING TODAY at 4:15pm ET: our Q3 2026 webinar with Samantha McLemore, CFA and Christina Siegel Malbon, CFA. Every day there’s a new AI bubble call. How do today’s AI stocks actually compare to 2000? We will cover 🔹 How we invest with conviction without predicting the future 🔹 What history can and can’t tell us about AI risk and opportunities 🔹 How today’s AI stocks compare to the 2000 tech bubble 🔹 Where rising rates are creating some of the most attractive opportunities we’ve seen in years Register here: zoom.us/webinar/register/491…

Join us Tuesday, October 20th for our Q3 2026 webinar, register here: zoom.us/webinar/register/491… When expectations are low, companies don’t need everything to go right for their stocks to work. Several stocks we purchased following sharp declines earlier in the year began to show traction. $ADBE started to recover from its lows, while payments names $CHYM, $GPN, and $ADYEN gained 30%, 13%, and 6%, respectively. $PGEN was our top contributor as the company continued to execute, and most importantly, received FDA platform designation for its AdenoVerse platform. We continue to focus on businesses that are out of favor when we believe the market is being overly negative. During the quarter, we entered positions in $AVGO and $META call options. Read our Q3 commentary for more on what drove performance, the new positions we entered, and where we continue to see opportunity: patientcapitalmanagement.com…

Looking backward, the course of events seems obvious. Looking forward, the possibilities are endless. In our latest quarterly letter, we examine: 🔹 Why successful investing doesn’t require knowing which path the future will take 🔹 How we’re thinking about the later stages of one of the longest and strongest bull markets in history 🔹 Why earnings durability is the main risk for AI companies, and the signal we’re watching most closely 🔹 How rising rates are creating some of the most attractive individual opportunities we’ve seen in yea The future will inevitably surprise us. Read the full commentary on our website: patientcapitalmanagement.com…

Register now for our Q3 2026 webinar on October 20th at 4:15pm ET➡️zoom.us/webinar/register/491… Q3 2026: Energy Rebounds, Value Takes the Lead, and Large Caps Outperform. The S&P 500 gained 2.3% on the quarter, with both the S&P 500 and the Nasdaq Composite reaching new all-time highs. Energy was the standout sector, rising 17.2% as renewed escalation in the war with Iran pushed crude prices back above $100 per barrel. Only 4 of 11 sectors posted a positive return. Value outperformed Growth, with the Russell 1000 Value Index gaining 2.6% versus 0.9% for the Russell 1000 Growth Index. Large caps led the quarter, with the Russell 1000 Index gaining 1.8%, while mid caps fell 3.0% and small caps declined 7.2%. Oil, gold, and Bitcoin all moved higher, rising 30.1%, 2.2%, and 42.6% respectively. Read our full Q3 2026 Market Review: patientcapitalmanagement.com…

SAVE THE DATE! Join us Tuesday, October 20th at 4:15pm ET for our Q3 2026 webinar. We'll cover what macro volatility could mean for markets, where we see opportunities amid the volatility, and why we remain optimistic over the long term. Submit your questions at registration for the live Q&A. REGISTER HERE: zoom.us/webinar/register/491…

What could a 5% 10-year Treasury yield mean for markets? Samantha McLemore, CFA, Founder and CIO, joined @CNBCTheExchange to share her perspective on rising rates and why we remain optimistic over the long term. She also discussed what she sees in QXO and more. Watch the full conversation here: patientcapitalmanagement.com…

We’re excited to share that @SamanthaMcLemor CFA, Founder and CIO, will return to @CNBCTheExchange with Kelly Evans on Monday, September 14, during the 1 p.m. ET hour! Make sure to tune in live! 🎥

Congratulations to our team and Precigen on all the progress since our 2024 investment! Precigen is a biopharmaceutical company developing next-generation gene and cell therapies. In 2024, Patient Capital led a capital raise for Precigen to help propel its mission to discover, develop and commercialize therapies for high unmet needs. Last week, the company reported strong results, adding to the progress of Papzimeos, a treatment that is helping patients who previously faced a devastating diagnosis with no good options. Seeing the progress makes this unique and differentiated investment especially meaningful to our team. We’re proud of our investment team for identifying a unique and differentiated opportunity that’s meaningfully improved patients’ lives, and delivered handsome investor returns. A win-win. We love investing like this, in a way that helps companies, patients and the broader world. *The information presented should not be considered a recommendation to purchase or sell any security and should not be relied upon as investment advice. It should not be assumed that any purchase or sale decisions will be profitable or will equal the performance of any security mentioned. References to specific securities are for illustrative purposes only and are not intended as a solicitation, or recommendation of any particular security or investment strategy.

We tend to look for answers where they’re easiest to find. For decades, the investment industry has relied on volatility as a proxy for risk. It brought rigor and discipline to investing, but over time, a useful measure increasingly became the definition of risk itself. In this month's edition of The Patient Perspective: Minding the Gap, Samantha McLemore, CFA examines what that distinction means for long-term investors and whether volatility tells us what really matters about investment risk. Read the full commentary on our website: patientcapitalmanagement.com…

In Case You Missed It! Our Q2 2026 Webinar Replay is now available. A few of our top takeaways: ➡️ The secular bull market still has room to run: We are in the later stages, but strong earnings and supportive valuations continue to support the market. Late-stage bull markets can also produce some of the strongest returns. ➡️ Earnings—not multiple expansion—are driving returns: Corporate earnings estimates continue to rise, providing a strong fundamental foundation for the market's advance. ➡️ Today's AI cycle is not the Tech Bubble: Semiconductor gains have been significant, but valuations remain far below 2000s levels. Nvidia trades near 21x earnings versus Cisco's peak of roughly 150x. ➡️ Volatility is creating opportunity: Rising single-stock volatility is pushing prices away from business fundamentals, creating attractive entry points for patient, valuation-driven investors. 🔗 Watch the full replay to hear @SamanthaMcLemor and @Christy_Malbon discuss today's AI-driven rally, the evidence behind AI infrastructure returns on capital, compute economics, and where they're finding compelling opportunities across the market: patientcapitalmanagement.com…

Markets continue to be driven by AI enthusiasm, but where are the opportunities beyond the obvious? Join @SamanthaMcLemor and @Christy_Malbon discuss today's market, recent portfolio activity, and where they're finding compelling opportunities across payments, software, biotech, healthcare, and more. HAPPENING TODAY! REGISTER HERE: zoom.us/webinar/register/441…

📅 Join us this Thursday, July 23 for our Q2 2026 webinar, register here: zoom.us/webinar/register/441… The best opportunities rarely begin as consensus favorites. In Q2 2026, the Opportunity Equity Strategy returned 17.3% net of fees, compared with 15.2% for the S&P 500. Health Care led the way. $UNH, $CVS, $PGEN benefited as fundamentals improved and the market began to recognize earnings potential that we believed had been overlooked. $RPRS, $ILMN, $BIIB also contributed, supported by durable cash flows, improving operating performance, and underappreciated growth opportunities. The common thread at initiation: high-quality assets, depressed expectations, and fundamentals not yet fully reflected in market prices. We are applying that same approach to payments, where concerns about competition have created what we believe are compelling opportunities in companies such as $ADYEN and $GPN. Our Q2 commentary explores where performance came from, where we are finding value today, and why investing ahead of shifts in sentiment remains central to our process. Full letter here ➡️ lnkd.in/eDsYQxYu

How does today's AI-driven rally compare to past market cycles? Join us one week from today, Thursday, July 23, as @SamanthaMcLemor and @Christy_Malbon discuss today's AI-driven rally, the evidence behind AI infrastructure returns, and why we continue to believe patience continues to be the optimal strategy. Register now and submit your questions in advance ➡️ zoom.us/webinar/register/441…

Markets continue to be driven by AI enthusiasm, but enthusiasm alone doesn't create investment returns. In our latest quarterly letter, we examine: 🔹 The surprising evidence on AI infrastructure investments’ returns on capital 🔹 Why recent compute economics may be even stronger than many appreciate 🔹 Why we're becoming more cautious on market sentiment while remaining optimistic on AI's long-term potential 🔹 Several new investments we've been adding during periods of weakness, true to our signature style Patience matters most when the market is focused on the next quarter. Read the full commentary on our website➡️patientcapitalmanagement.com…

Q2 2026: AI Infrastructure Boom, Tech's Comeback, and a Return to Growth Leadership. The S&P 500 gained 15.20% on the quarter, a sharp reversal from Q1's pullback. Info Tech was the standout sector, gaining 31.79%, fueled by surging AI infrastructure demand and a memory chip shortage that pushed semiconductor stocks higher. Growth outperformed Value, flipping the trend of the last two quarters, with the Russell 1000 Growth Index gaining 16.7% versus 13.9% for Value. Small caps led the quarter, with the Russell 2000 Index gaining 21.6%, outperforming both large and mid caps. Oil, gold, and Bitcoin all pulled back, declining 31.4%, 14.3%, and 14.0% respectively. DETAILS: lnkd.in/eiNn5zmD Stocks just posted their best quarter in 6 years powered by a historic run in semiconductors. Want to learn where we're finding opportunities? Join our Q2 2026 webinar on July 23rd. Register here ➡️ zoom.us/webinar/register/441…

SAVE THE DATE! 📅 Join us Thursday, July 23rd at 4:15pm ET for our Q2 2026 webinar. We'll cover the current market backdrop, portfolio positioning, and where we're finding value right now. Plus, a live Q&A - submit your questions at registration. REGISTER HERE: zoom.us/webinar/register/441…

Last week, Founder & CIO, Samantha McLemore, CFA joined @TheJudgeCNBC on @CNBCClosingBell. Are we in a bubble? Has it gone too far? That question has been circulating for over a year. "We've mostly just seen the moves track the earnings." With a strong earnings season underway, she sees this as a secular bull market, not a bubble and believes valuations are keeping pace with fundamentals. Watch the full segment on our website: patientcapitalmanagement.com… Read her full quote in CNBC's live market update: cnbc.com/2026/05/06/stock-ma…

Happening today! @SamanthaMcLemor will join @TheJudgeCNBC on @CNBCClosingBell. Tune in at 3:45pm ET to watch live!

Our Founder and CIO, @SamanthaMcLemor, is heading back to CNBC's Closing Bell with Scott Wapner this Wednesday, May 6th in the 3pm ET hour. Tune in to hear her live market outlook amid ongoing volatility, her read on the Tech/AI trade, and the sectors and stocks she thinks investors should have their eye on right now.

In Case You Missed It! Our 1Q 2026 Webinar Replay is now available. A few of our top takeaways: ➡️ The secular bull market is still intact: Despite headlines and macro noise, the underlying signal remains strong. ➡️ Earnings are the key driver: Market strength is coming from unusually strong corporate earnings growth, not multiple expansion. ➡️ Volatility is more often an opportunity than a risk: Pullbacks create the best entry points. The real risk is permanent capital loss, not short-term price moves. ➡️ Dispersion is creating a stock picker's market: Extreme moves across sectors and individual names are creating one of the most attractive environments for active management in years. 🔗 Watch the full replay to hear @SamanthaMcLemor and @Christy_Malbon discuss compelling risk-reward opportunities like $ADBE, $RPRX, $PGEN, and $AMZN: patientcapitalmanagement.com…